ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome

S. Radunz1, A. Kirschner1, J. M. Theysohn2, C. Schotten3, T. Benkö1

1General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, 2Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, 3Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany

Meeting: 2019 American Transplant Congress

Abstract number: D122

Keywords: Hepatocellular carcinoma, Liver, Liver transplantation, Tumor recurrence

Session Information

Session Name: Poster Session D: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective of our study was to evaluate the rate of complete pathologic response in patients undergoing locoregional bridging treatment, to analyze the effect of complete pathologic response on post-transplant recurrence, and identify factors that predict the ability to achieve complete pathologic response after undergoing locoregional bridging treatment.

*Methods: We performed a retrospective review of all adult patients who underwent liver transplantation for HCC between January 2007 and December 2017 in our transplant center. Locoregional bridging therapies included radiofrequency ablation, TACE, radioembolization or a combination of the above. The type and number of treatment as well as the time from last treatment to liver transplantation was recorded.

*Results: On explant specimen, complete pathologic tumor necrosis was achieved in 35.4% of patients while 64.6% of patients achieved partial or no tumor necrosis. There were no differences regarding age, gender, underlying liver disease, MELD score and Milan criteria in patients with complete tumor necrosis compared to patients without. Patients with treatment response had significantly smaller (28 [12-175] vs. 36 [12-225] mm, p 0.0023) and less tumor nodules (>3 nodules in 20.7% vs. 37.4%, p 0.0278). Pre-treatment AFP was lower in the complete response group, however, this did not reach statistical significance (14.1 [1.1-43611.0] vs. 28.0 [1.1-538184.0] IU/ml, p 0.0760). On explant specimen, poor differentiation (1.6% vs. 21.7%, p 0.0003) and microvascular invasion (0.0% vs. 20.0%, p 0.0001) was significantly less frequently present in the complete response group. In the entire cohort, 16.3% of patients developed recurrent HCC. Tumor recurrence was significantly less frequent among patients with complete treatment response (3.2% vs. 23.5%, p 0.0005). Multivariate analysis detected tumor size and numbers as well as poor differentiation being individually associated with decreased odds of treatment response.

*Conclusions: Successful bridging treatment leading to complete necrosis may facilitate successful liver transplantation in HCC patients. Treatment response is less likely achieved in tumors of large numbers or size and poor differentiation.

Tumor characteristics
Complete necrosis Without necrosis p
Maximum tumor size (mm) 28 [12-175] 36 [12-225] 0.0023
Multifocal tumor lesions (%) 20.6 37.4 0.0278
AFP (IU/ml) 14.1 [1.1-43,611.0] 28.0 [1.1-583,184.0] 0.0760
Poor differentiation (%) 1.6 21.7 0.0003
Microvascular invasion (%) 0.0 20.0 0.0001
Tumor recurrence (%) 3.2 23.5 0.0005

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Radunz S, Kirschner A, Theysohn JM, Schotten C, Benkö T. Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/tumor-necrosis-as-a-result-to-pre-transplant-bridging-treatment-for-hepatocellular-carcinoma-and-its-effect-on-post-transplant-outcome/. Accessed May 18, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences